Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease

Digestive Diseases and Sciences

Volumn 60, Issue 11, 2015, Pages 3424-3430

  George, Lauren A ^a   Gadani, Akash ^a   Cross, Raymond K ^a,b   Jambaulikar, Guruprasad ^b   Ghazi, Leyla J ^a,b,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c Veterans Affairs   (United States)

Author keywords

Anti TNF; Inflammatory bowel disease; Psoriasiform rash; Tobacco use

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; INFLIXIMAB; METHOTREXATE; STEROID; USTEKINUMAB; ANTIINFLAMMATORY AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; CAUCASIAN; CLINICAL DATA REPOSITORY; CLINICAL FEATURE; CONTROLLED STUDY; CROHN DISEASE; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; RASH; RECURRENT DISEASE; SMOKING; SYSTEMIC THERAPY; TERTIARY CARE CENTER; TOPICAL TREATMENT; TRUNK; ULCERATIVE COLITIS; UPPER GASTROINTESTINAL TRACT; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; COLITIS, ULCERATIVE; DRUG ERUPTIONS; IMMUNOLOGY; MULTIVARIATE ANALYSIS; ODDS RATIO; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL PRODUCTS; CHI-SQUARE DISTRIBUTION; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG ERUPTIONS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; ODDS RATIO; PSORIASIS; RETROSPECTIVE STUDIES; RISK FACTORS; TERTIARY CARE CENTERS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84945447944     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3763-0     Document Type: Article

References (29)

1. Loftus CG, Loftus EV, Harmsen WS, et al. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflamm Bowel Dis. 2007;13:254–261.
2. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterol. 2005;128:862–869.
3. Lindsay JO, Chipperfield R, Giles A, Wheeler C, Orchard T. A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn’s disease. Aliment Pharmacol Ther. 2013;38:52–61.
4. Abraham NS, Richardson P, Castillo D, Kane SV. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:1281–1287.
5. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel J-F. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644–653.
6. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 2005;52:2513–2518.
7. Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2009;68:209–215.
8. Kip KE, Swoger JM, Grandinetti LM, Barrie AM 3rd, Greer JB, Regueiro MD. Tumor necrosis factor antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system. Inflamm Bowel Dis. 2013;19:1164–1172.
9. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2–6; discussion 16–19.
10. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19:5–36.
11. Afzali A, Wheat CL, Hu JK, Olerud JE, Lee SD. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series. J Crohn’s Colitis. 2014;8:480–488.
12. Guerra I, Algaba A, Pérez-Calle JL, et al. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohn’s Colitis. 2012;6:518–523.
13. Parisi R. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Investig Dermatol. 2013;133:377–385.
14. Icen M. Trends in incidence of adult onset psoriasis over three decades: a population based study. J Am Acad Dermatol. 2009;60:394–401.
15. Wolk K. Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis. Acta Dermato Venereol. 2009;89:492–497.
16. Rahier J-F, Buche S, Peyrin-Biroulet L, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8:1048–1055.
17. Denadai R, Teixeira FV, Steinwurz F, Romiti R, Saad-Hossne R. Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J Crohn’s Colitis. 2013;7:517–524.
18. Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol. 2012;67:e179–e185.
19. Skroza N, Proietti I, Pampena R, et al. Correlations between psoriasis and inflammatory bowel diseases. BioMed Res Int 2013;2013:1–8.
20. Barthel C, Biedermann L, Frei P, et al. Induction or exacerbation of psoriasis in patients with Crohn’s disease under treatment with anti-TNF antibodies. Digestion. 2014;89:209–215.
21. Huang V, Dhami N, Fedorak DK, et al. 3 infliximab trough levels are correlated with infliximab-associated adverse events. Gastroenterol. 2014;146:S-1.
22. Protic M, Münger C, Seibold F. Sa1267 psoriasis induced by anti TNF treatment in patients with inflammatory bowel disease—a single center study. Gastroenterol. 2014;146:S-247–S-248.
23. Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR. Psoriasis associated with anti tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34:1318–1327.
24. Berth-Jones J. A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician’s Global Assessment and Lattice System Physician’s Global Assessment. Br J Dermatol. 2006;155:707–713.
25. Mattozzi C. Psoriasis: new insight about pathogenesis, role of barrier organ integrity, NLR/CATERPILLER family genes and microbial flora. J Dermatol. 2012;39:752–760.
26. Di Cesare A. The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis. J Invest Dermatol. 2009;129:1339–1350.
27. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40:233–240.
28. Fiorino G, Danese S, Pariente B, Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmun Rev. 2014;13:15–19.
29. Włodarczyk M, Sobolewska A, Wójcik B, Loga K, Fichna J, Wiśniewska Jarosińska M. Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn’s disease patients. World J Gastroenterol. 2014;20:7019–7026.